A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel-hyaluronic acid conjugate (Primary)
Indications Bladder cancer
Focus Registrational; Therapeutic Use
Sponsors Fidia Farmaceutici

Most Recent Events

18 Jan 2023 Status changed from not yet recruiting recruiting.
18 Jan 2023 Planned End Date changed from 1 Jul 2027 to 1 Nov 2027.
18 Jan 2023 Planned primary completion date changed from 1 Jul 2025 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight